KR20190036974A - Anti-inflammation Composition and Anit-allergy Composition Using an Extract of Polygonum perfoliata - Google Patents

Abstract

The present invention relates to an anti-inflammation and anti-allergic composition using an extract of Persicaria perfoliata, which inhibits the production of nitric oxide (NO) in macrophages stimulated by LPS (lipopolysaccharide) in a concentration-dependent manner, and also inhibits degranulation in the concentration-dependent manner when being treated to a mast cell line RBL-2H3 (rat basophilic leukemia) activated by IgE and antigen (DNP-BSA).

Description

The present invention relates to an anti-inflammatory and anti-allergy composition using a navel extract,

The present invention relates to an anti-inflammatory and anti-allergic composition using a Polygonum perfoliata extract.

Due to various factors such as environmental change due to rapid industrial development of modern society, westernization and increasing stress, inflammation and allergic diseases related to abnormality of immune control function are increasing rapidly.

Inflammatory responses are mechanisms of defense against internal and external physical and chemical stimuli and various infectious agents including tissue damage (Zamora R et al., Mol. Med. 6: 347-373 (2000); Mariathasan S and Monack DM. Nat. Rev. Immunol. 7: 31-40 (2007); Lee HN et al., J. Food Sci. Technol. 43: 65-71 (2011)). During the inflammation reaction, plasma accumulates on the inflamed area, diluting the toxicities secreted by the bacteria, increasing the blood flow, and accompanied by symptoms such as erythema, pain, edema, and fever. The persistent inflammatory response causes tissue damage and induces progression to the stomach, colon, bladder, and prostate cancer, leading to various diseases such as rheumatoid arthritis and chronic infection (Hofseth LJ and Ying L. Biochim. Biophys. Acta 1765 USA, 88: 7773-7777 (1991), pp. 74-84 (2006); Yun HY et al., Rev. Neurobiol. 10: 291-316 (1996); Stuehr DJ et al., P. Natl. Acad. ).

(IL-1β), IL-6, IL-6, IL-6, IL-6, IL-6, IL-6, and IL-6 in the presence of inflammatory mediators such as macrophages and monocytes. 8, and IL-12 (Guha M and Mackman N. Cell Signal. 13: 85-94 (2001)). A typical example of an inflammatory response is activation of the toll like receptor (TLR) signaling pathway of macrophages by pathogen associated molecular patterns (PAMPs). Lipopolysaccharide (LPS), a type of endotoxin present in the outer membrane of gram-negative bacteria, belongs to the inflammatory mediator PAMPs present in external microorganisms. TLR4 recognizes LPS with the help of MD-2 or CD14 (Miyake K. Trends Microbiol. 12: 186-192 (2004)), and the lower signaling pathway (NF-κB), which is a transcription factor, which activates NF-κB (NF-κB). Food Sci. Technol. 41: 477-482 (2009)). NF-κB translocated to the nucleus was found to be an inflammatory cytokine (TNF-α, IL-1β, IL-6, IL-8 and IL-12), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 Nitric oxide (NO) induced by iNOS induces gene expression and exacerbates inflammation (Noh KH et al., J. Korean Soc. Food Sci. Nutr. 40: 625-634 (2011) ; Weisze et al., Biochem. J. 316: 209-215 (1996)). Nitric oxide, which is produced by iNOS in macrophages, reacts with superoxide to form peroxynitrite, which acts as a strong oxidizing agent and damages the cells, resulting in a variety of pathologies including inflammation and cancer (Gupta SC et al., Exp Biol Med., 236: 658-671, (2011); Riehemann et al., FEBS Lett., 442: 89-94 (1999)).

Allergy refers to that the immune system in the body is excessively adversely affected by external foreign matter or external environmental stimulus, causing pollenosis, urticaria, rhinitis, asthma, atopy and the like. For others, problematic substances can cause allergies to certain people. It is also classified as an environmental disease because it is caused by external stimuli.

Mast cells and basophils are known to be the major cells causing allergic diseases through secretion of allergen-induced inflammatory mediators by antigen stimulation (Blank, U. et al., Allergy 68.9: 1093-101. (2013), Schroeder JT Adv Immunol 101: 123-61 (2009), Galli, SJ New Eng J. Med. 328: 257-265 (1993)). When a human is exposed to a specific antigen such as food, house dust mite, mite, pollen, etc., T-helper cell and B cell are sequentially activated and IgE is generated, thereby activating mast cell and activating allergic reaction (Metcalfe DD et al., Crit. Rev. Immunol. 3: 23-74 (1981); Church MK and Levi-Schaffer FJ Allergy Clin. Imm. 99: 155-60 (1997)). Histamine, β-hexosaminidase, and serotonin are secreted by the degranulation of mast cells. Histopathologic reactions such as urticaria and rash are produced by secretion of newly synthesized lipid mediators. T helper type 2 (Th2), eosinophil, neutrophil , Mononuclear cells, and the like, activate cytokine synthesis and secretion, thus continuing the inflammatory infiltration response (Chang et al., 2006); Alulgy Clin Immunol 117 (6) K. et al., Cellular Molecular Immunology, 6th Edition, Seoul: The Public, 191-217, 451-71 (2008), Schwartz LB et al., J Immunol 126 (4): 1290-4 1981))

Although synthetic medicines such as ibuprofen, antihistamines, steroids, cortisone, immunosuppressants, and immunosuppressive agents are used in inflammatory and allergic treatments, there are many side effects such as temporary treatment effects, simple symptom relief, hypersensitivity, and immune system worsening. Is difficult. Because of the tolerance of steroids, the use of increasingly strong preparations may result in no further therapeutic effects and may lead to other side effects such as obesity, diabetes, hypertension and depression. In addition, antihistamines suppress the movement of mast cells in the blood vessels, so symptoms such as runny nose, diarrhea, sneezing, and cough are alleviated. However, when taken over a long period, it causes depression, concentration difficulty and lethargy, And causes side effects such as drowsiness, sexual dysfunction, and hepatic disorder.

Therefore, it is necessary to develop anti-inflammatory or allergic drugs that can reduce the dosage of steroid and antihistamine drugs and that are safe for long-term use.

The present invention discloses an anti-allergic and anti-inflammatory activity of a wombat extract of a daughter-in-law.

It is an object of the present invention to provide an anti-inflammatory and anti-allergic composition using a bee venom extract.

Other and further objects of the present invention will be described below.

The present invention relates to a method for inhibiting the production of nitric oxide (NO) in macrophages stimulated by LPS (lipopolysaccharide) in a concentration-dependent manner, as well as inhibiting concentration of IgE and antigen (DNP -BSA) -activated mast cell line RBL-2H3 (rat basophilic leukemia) inhibited the degranulation in a concentration-dependent manner.

In view of the above, the present invention can be regarded as an anti-allergy composition comprising an extract of Aryeum japonica as an active ingredient in one aspect and an anti-inflammatory extract comprising an Aleuria larvae extract as an active ingredient in another aspect . In yet another aspect, the antihistamine composition or the composition for suppressing the formation of NO (NO) may be used as an effective ingredient for the extract of Aurorhynchus sinensis.

In the present specification, the "daughter-in-law's belly extract" refers to water, a lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, butanol Etc.), methylene chloride, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, N, N-dimethylformamide (DMF), dimethylsulfoxide (DMSO) Or an extract obtained by leaching using a mixed solvent thereof, an extract obtained by using a supercritical extraction solvent such as carbon dioxide or pentane, or a fraction obtained by fractionating the extract, and the extraction method is a method of extracting the polarity, It is possible to apply any method such as cold rolling, reflux, warming, ultrasonic irradiation, supercritical extraction, and the like. In the case of the fractionated extract, a fraction obtained by suspending the extract in a specific solvent and mixing and leaving with a solvent having a different polarity, the crude extract is adsorbed on a column packed with silica gel, and then a hydrophobic solvent, a hydrophilic solvent, Quot; means fractions obtained as a mobile phase. Also, the meaning of the extract includes a concentrated liquid extract or a solid extract in which the extraction solvent is removed by a method such as freeze drying, vacuum drying, hot air drying, spray drying and the like. Preferably means an extract obtained by using water, a lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, butanol, etc.) or a mixed solvent thereof as an extraction solvent.

In the present specification, the term " active ingredient " alone means an ingredient which exhibits the desired activity or which can exhibit activity together with a carrier which is not itself active.

In the present specification, the term " anti-allergy " is meant to include improvement (symptom relief), treatment, prevention (prevention or delay of onset) of an allergic disease as defined below.

In the present specification, the term " allergic disease " means a pathological symptom caused by an allergic reaction mediated by mast cell activation such as degranulation of mast cells. Such allergic diseases include atopic dermatitis, asthma, Allergic rhinitis, allergic conjunctivitis, allergic dermatitis, allergic contact dermatitis, and the like. The term " allergic contact dermatitis "

In the present specification, " antihistamine " means physiological change due to excessive secretion of histamine or improvement of the disease caused by dysfunction. The physiological changes caused by the secretion of histamine or diseases caused by dysfunction include allergic diseases such as nasal obstruction, dizziness, vomiting, hyperacidity, gastroesophageal reflux disease, inflammation, hypotension associated with anapalacsis .

As used herein, " anti-inflammatory " is meant to include improvement of an inflammatory disease (alleviation of symptoms), treatment, inhibition or delay of onset of such a disease as defined below.

In the present specification, the term " inflammatory disease " refers to an inflammatory disease caused by an external physicochemical stimulus or an infection of an external infectious source such as bacteria, fungi, viruses, various allergenic substances, or a local or systemic defense against autoimmunity It may be defined as a pathological symptom. These inflammatory reactions include activation of various inflammatory mediators and enzymes associated with immune cells such as iNOS and COX-2, secretion of inflammatory mediators such as NO, TNF-, and IL-6 secretion, Migra- tion, and tissue destruction, and manifest externally by symptoms such as erythema, pain, swelling, fever, deterioration or loss of specific functions of the body. The inflammatory disease may be acute, chronic, ulcerative, allergic or necrotic, so that as long as any disease is included in the definition of inflammatory diseases as described above, it may be acute, chronic, ulcerative, Whether it is necrotic or not. Specifically, the inflammatory diseases include asthma, allergic and non-allergic rhinitis, chronic and acute rhinitis, chronic and acute gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, Inflammatory bowel syndrome, inflammatory pain, migraine headache, headache, back pain, fibromyalgia, fascia disease, viral infection (e.g., C type infection), bacterial infection, fungal infection, burn, wound due to surgical or dental surgery, Rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, iritis, scleritis, uveitis, dermatitis (including atopic dermatitis), eczema, multiple sclerosis, etc. Will be included.

The anti-inflammatory and anti-allergic composition of the present invention may be contained in any amount (effective amount) as long as it can exhibit improving activity of an inflammatory disease, an allergic disease, etc. intended to be treated according to the purpose of use, formulation, , A typical effective amount will be determined within the range of from 0.001% to 15% by weight based on the total weight of the composition. The term " effective amount " as used herein refers to an amount of an effective amount of the compound of the present invention to be administered to a mammal, preferably a human, to which the composition of the present invention is administered during a period of administration, Refers to the amount of active ingredient that can exhibit medical and pharmacological effects such as inhibiting / delaying onset of symptoms. Such effective amounts can be determined experimentally within the ordinary skill of those skilled in the art.

The anti-inflammatory, anti-allergic composition, etc. of the present invention can be used as an anti-inflammatory, anti-allergic, and the like in addition to the active ingredient. In order to improve the dosage, ingestion and ease of use through addition, it may further comprise any compound or natural extract already known in the art to be safe and known to have a corresponding activity.

These compounds or extracts include the national pharmacopoeia (Korean pharmacopoeia), the national health functional food circulation in Korea (in Korea, the health functional food standard and specification), the functional cosmetics circulation in each country (in Korea, Compounds or extracts listed in the official documents such as "Functional Cosmetics Standards and Test Methods"), compounds or extracts approved by the respective countries in accordance with the laws of the respective countries (in Korea, "Pharmaceutical Affairs Law") regulating the manufacture and sale of pharmaceuticals In accordance with the laws of each country that regulate the manufacture and sale of compounds or extracts and functional cosmetics that are recognized as functioning in accordance with the laws of the respective countries ("Act on Health Functional Foods" in Korea) that regulate the manufacture and sale of functional foods &Quot;), and the like.

Examples of such ingredients include dry powder of Enterococcus faecalis heat treatment treated with the function of 'hypersensitive immune response' function according to the Korean Health Functional Food Act, complexes such as guava leaf extract, extract of Quercus alba, extract of lobules, complexes, and PLAG (1-palmitoyl-2- linoleoyl-3-acetyl-rac-glycerol), ' improve skin hypersensitivity condition "functionality is the recognition L. sakei Probio 65, gamma-linolenic acid-containing oil, gwachae derived from lactic acid bacteria (L.plantarum CJLP133), probiotics ATP, etc., and MSM (MSM), which has been approved for the improvement of arthritis in the Health Functional Food Code dimethylsulfonylmethane), N-acetylglucosamine, glucosamine, and CMO containing complex extracts such as FAC (Fatty acid Complex) and ganoderma lucidum, turmeric extract, chicken breast cartilage powder, rosehip powder, Complex extracts such as Swellia extract, Beeswax alcohol and Fennel extract, Compound extracts such as fatty acid complexes and extracts, Green lipped mussel extract oil, Hope extract, Golden extract, etc., and cosmetic products according to Korea Cosmetic Act , And cosmetics such as arbutin, niacinamide, ascorbyl glucoside, alpha-bisabolol and oil soluble licorice (Glycyrrhiza extract), which are recognized as skin whitening ingredients, Retinol, retinyl palmitate, adenosine, polyethoxylated amide, which are recognized as anti-wrinkle ingredients in the revolution, and the like, as well as drometrizol, drometrizol trisiloxane, Yl trioleate, Dimethicone fulvene benzal malonate, diethylacetambutamidotriazone, Complex extracts such as pine bark extract, phosphatidylserine, finger root extract powder, and complex extracts of red ginseng and corn oil. Such ingredients may be included in the compositions of the present invention in combination with one or more of their effectiveness.

The anti-inflammatory, anti-allergic composition, etc. of the present invention can be grasped as a food composition in a specific embodiment.

The food composition of the present invention can be produced in any form and can be used in various forms such as beverages such as tea, juice, carbonated drink, ionic drink, processed oil such as milk and yogurt, gum, rice cake, Korean confectionery, A food, a health food, a food, a tablet, a capsule, a ring, a granule, a liquid, a powder, a slice, a paste, a syrup, a gel, a jelly and a bar.

In addition, the food composition of the present invention may be classified into any product category as long as it meets the laws and regulations on the time of manufacture and distribution in the legal and functional category. For example, it is a health functional food under the laws of foreign countries that regulate the manufacture and sale of health functional foods (in Korea, the "Health Functional Food Act"), or foreign laws regulating the manufacture and sale of foods (Korean Food Standards and Standards), which is the Food Standards Act of Korea (in Korea, the Food Sanitation Law), may be confectionery, pulses, bean oil, fermented beverages, special-purpose foods, etc. according to each food type.

The food composition of the present invention may contain food additives in addition to the active ingredients thereof. Food additives are generally understood to be substances that are added to foods and mixed or infiltrated into food in the manufacture, processing or preservation of food, and their safety must be ensured since they are ingested daily with food and for long periods of time. In food additives according to the laws of the respective countries ("Food Sanitation Act" in Korea) regulating the manufacture and distribution of food, food additives with safety are specified in terms of ingredient or function. In the Food Additives Code of Korea (Food Additives Standards and Standards), the food additives are classified into chemical compounds, natural additives and mixed preparations in terms of ingredients. Such food additives are classified into sweeteners, flavors Preservatives, emulsifiers, acidulants, and thickeners.

These functional food additives can be classified into sweeteners, flavors, preservatives, emulsifiers, acidifiers, and thickeners.

A sweetener is used to impart a sweet taste suitable for foods, and natural or synthetic sweeteners can be used. Preferably, natural sweeteners are used. Examples of natural sweeteners include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose and maltose.

Flavors may be used to enhance taste or flavor, both natural and synthetic. Preferably, a natural one is used. When using natural ones, the purpose of nutritional fortification can be performed in addition to the flavor. Examples of natural flavoring agents include those obtained from apples, lemons, citrus fruits, grapes, strawberries, peaches, and the like, or those obtained from green tea leaves, Asiatica, Daegu, Cinnamon, Chrysanthemum leaves and Jasmine. Also, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, banks and the like can be used. The natural flavoring agent may be a liquid concentrate or a solid form of extract. Synthetic flavors may be used depending on the case, and synthetic flavors such as esters, alcohols, aldehydes, terpenes and the like may be used.

As the preservative, calcium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate and EDTA (ethylenediaminetetraacetic acid) can be used. As the emulsifier, acacia gum, carboxymethyl cellulose, Pectin and the like. As the acidulant, math, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid and the like can be used. The acidulant may be added so that the food composition has a proper acidity for the purpose of inhibiting the growth of microorganisms other than the purpose of enhancing the taste.

Examples of the thickening agent include suspending agents, sedimentation agents, gel-forming agents, bulking agents and the like.

The food composition of the present invention may contain physiologically active substances or minerals which are known in the art and which are stable as a food additive in addition to the above-mentioned food additives in order to supplement and supplement functional and nutritional properties.

Examples of such physiologically active substances include catechins contained in green tea and the like, vitamins such as vitamin B1, vitamin C, vitamin E and vitamin B12, tocopherol, dibenzoyl thiamine, etc. Examples of minerals include calcium preparations such as calcium citrate, magnesium stearate , Iron preparations such as iron citrate, chromium chloride, potassium iodide, selenium, germanium, vanadium, zinc and the like.

The food composition of the present invention may contain an appropriate amount of the above-mentioned food additives according to the product type so as to achieve the purpose of addition thereof.

With regard to other food additives that can be included in the food composition of the present invention, reference may be made to the Food Code or the Food Additive Code.

The anti-inflammatory and anti-allergic composition of the present invention can be identified as a pharmaceutical composition in another specific embodiment.

The pharmaceutical composition of the present invention may be prepared into oral formulations or parenteral formulations according to the route of administration by conventional methods known in the art, including pharmaceutically acceptable carriers in addition to the active ingredient. The term " pharmaceutically acceptable " as used herein means that the application (prescribing) subject does not have the above-mentioned toxicity that is adaptable without inhibiting the activity of the active ingredient.

When the pharmaceutical composition of the present invention is prepared into an oral formulation, it may be formulated into powder, granules, tablets, pills, sugar tablets, capsules, solutions, gels, syrups, suspensions, wafers And the like. Examples of suitable pharmaceutically acceptable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, xylitol, starch such as corn starch, potato starch and wheat starch, cellulose, methylcellulose, ethylcellulose, Cellulose derivatives such as sodium carboxymethyl cellulose and hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, And the like. In case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, and / or an excipient may be formulated according to need.

When the pharmaceutical composition of the present invention is prepared into a parenteral dosage form, it may be formulated in the form of an injection, transdermal drug delivery, nasal aspirate and suppository together with a suitable carrier according to methods known in the art. Examples of suitable carrier in the case of formulation with an injectable preparation include sterilized water, ethanol, polyol such as glycerol and propylene glycol, or a mixture thereof. Preferably, the carrier is selected from the group consisting of Ringer's solution, phosphate buffered saline containing triethanolamine, Water, or isotonic solution such as 5% dextrose may be used. When formulated with a transdermal drug, it can be formulated in the form of an ointment, a cream, a lotion, a gel, a solution for external use, a pasta, a liniment, or an air-roll. The nasal inhalant may be formulated in the form of an aerosol spray using a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc. When formulated as a suppository, witepsol, tween 61, polyethylene glycols, cacao butter, laurin, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, and sorbitan fatty acid esters.

The formulation of pharmaceutical compositions is well known in the art and can be specifically described in Remington ' s Pharmaceutical Sciences (19th ed., 1995). This document is considered part of this specification.

The preferred dosage of the pharmaceutical composition of the present invention is 0.001 mg / kg to 10 g / kg per day, preferably 0.001 mg / kg to 1 g / day, depending on the patient's condition, body weight, sex, age, / kg < / RTI > The administration can be carried out once or several times a day. Such dosages should in no way be construed as limiting the scope of the invention.

The anti-inflammatory, anti-allergic composition of the present invention can be identified as a cosmetic composition in another specific embodiment. When the anti-allergic composition or antihistamine composition of the present invention is identified as a cosmetic composition, its use can be understood as alleviation of allergic skin irritation. When the anti-inflammatory composition of the present invention is identified as a cosmetic composition, It can be understood as a relief of stimulation.

Even when the composition of the present invention is identified as a cosmetic composition, the cosmetic composition may be classified into any product category according to the use of the cosmetic composition. Specifically, the cosmetic composition may be a functional cosmetic having a use such as skin whitening, . Specific examples of the product form include a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing oil, powder foundation, emulsion foundation, wax Foundation, spray or the like. In a specific product form, it may be a form of flexible lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

The cosmetic composition of the present invention may contain, in addition to its active ingredient, conventional additives such as stabilizers, solubilizing agents, surfactants, vitamins, colorants and antioxidants, and carriers commonly used in cosmetic compositions.

The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used in the form of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.

When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component is selected from aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.

The cosmetic composition of the present invention can be produced by a method for producing a cosmetic composition which is usually carried out in the art, except that it contains the active ingredient exhibiting anti-inflammation, anti-allergic activity and the like.

As described above, according to the present invention, an anti-inflammatory and anti-allergic composition using a nematode extract can be provided.

The anti-inflammatory, anti-allergic composition, etc. of the present invention can be commercialized into foods, medicines, cosmetics and the like.

Fig. 1 shows the results of demonstrating the degranulation inhibitory activity of the larvae extract of a daughter-in-law.

Hereinafter, the present invention will be described with reference to Examples and Experimental Examples. However, the scope of the present invention is not limited to these examples and experimental examples.

EXAMPLES Preparation of a Belly Extract

20 times the weight of 70 % ethanol was added to the navel of a daughter-in-law (outpost, please check), and leached for 24 hours. Then, the mixture was filtered with a filter paper No. 2 of whatman paper. The filtrate was concentrated under reduced pressure, .

≪ Experimental Example > Experiment of anti-inflammatory and anti-allergic activity

Experimental Example 1: Anti-inflammatory experiment

To evaluate the intracellular anti-inflammatory activity of the extract of Example of the present invention in mouse macrophage RAW264.7 cells, cells were seeded at a density of 5 × 10 ⁴ cells / well in a 96-well plate and cultured at 37 ° C. in 5% CO ₂ for 24 hours Lt; / RTI > The samples were treated with 96-well plates for 1 hour, and treated with 1 μg / ml of LPS (Lipopolysacharide) for 24 hours. To evaluate the anti-inflammatory activity through the NO assay, 1% sulfanilamide and 0.1% N- (1-naphtyl) ethylenediamine dihydrochloride reagent were mixed in a ratio of 1: 1 using griess A and B reagents. After incubation at 37 ° C and 5% CO ₂ for 24 h, the supernatant of the culture medium was mixed with the griess (A + B) reagent at a ratio of 1: 1 and stored at room temperature for 10 min. , And the IC ₅₀ was determined by measuring the inhibitory effect of NO production on the control group, which was not treated with the sample, by ELISA measurement at 540 nm. As a result, IC ₅₀ was 52.23 ㎍ / ml.

Cytotoxicity was measured by MTT assay. Specifically, the medium remaining in the 96-well plate was removed, and 100 μl of a 10% serum-free medium containing 5 mg / ml MTT solution was added to each well. The cells were incubated at 37 ° C in a 5% CO ₂ incubator for 2 hours. After removing the medium, DMSO was added to 100 μl / well and dissolved in a shaker for 15 minutes. The absorbance was measured at 540 nm using an ELISA reader to determine the cell viability and the toxicity of the sample was confirmed. No specific cytotoxicity was observed at the highest treatment concentration of 100 ㎍ / ml.

<Experimental Example 2> Anti-allergic activity test

The RBL-2H3 cell line, a Rat basophilic leukemia cell line, was cultured in MEM medium containing 15% FBS, 100 units / ml penicillin and streptomycin at 37 ° C and 5% CO ₂ in a 24-well plate at 2 × 10 ⁵ / well Followed by incubation for 24 hours.

The supernatant was removed and MEM medium containing 25 ng / ml anti-DNP IgE was added and cultured for 4 hours. After incubation, the cells were washed twice with PIPES buffer (25 mM PIPES, 119 mM NaCl, 5 mM KCl, 1 mM CaCl ₂ , 0.4 mM MgCl ₂ , 40 mM NaOH, 5.6 mM glucose, 0.1% BSA) and incubated with PIPES buffer for 10 minutes. After incubation, the samples of the examples were treated for 20 minutes at a concentration, and DNP-BSA was added thereto, followed by reaction for 20 minutes. Ice was left for 10 minutes to terminate the reaction. The supernatant was added to a 96-well plate, and 1 mM P-nitrophenyl-acetyl-β-D-glucosaminyl was added thereto, followed by reaction at 37 ° C. for 1 hour. stop solution (0.1 M NaHCO ₃ , 0.1 M Na ₂ CO ₃ ), and the absorbance was measured with an ELISA reader at a wavelength of 405 nm. Ketotifen was used as a positive control.

The results are shown in Fig. 1 as a percentage of the untreated group. Referring to FIG. 1, it can be seen that the saphenous juice extract inhibits degranulation in a concentration-dependent manner.

Claims (10)

An antiinflammatory composition comprising a navel extract of a daughter-in-law as an active ingredient.
The method according to claim 1,
Wherein the extract is an extract obtained by extracting with water, ethanol or a mixed solvent thereof.
3. The method according to claim 1 or 2,
Wherein the composition is a pharmaceutical composition.
3. The method according to claim 1 or 2,
Wherein the composition is a food composition.
3. The method according to claim 1 or 2,
Wherein the composition is a cosmetic composition.
A composition for anti-allergy comprising an extract of Aurorhynchos grandiflorum as an active ingredient.
The method according to claim 6,
Wherein the extract is an extract obtained by extracting with water, ethanol or a mixed solvent thereof.
8. The method according to claim 6 or 7,
Wherein the composition is a pharmaceutical composition.
8. The method according to claim 6 or 7,
Wherein the composition is a food composition.
8. The method according to claim 6 or 7,
Wherein the composition is a cosmetic composition.

Images